Serum glucose concentration and lipid profile in racing horses

The aim of the present work was to evaluate serum glucose concentration and lipid profile in racing horses in Iraq. Blood samples were collected from the jugular vein of 92 clinically healthy racing horses (males and females, Arabian and Cross bred), 2-8 years old at Equestrian Club, Baghdad. Investigations included serum measurements of glucose (sg) and lipid profile parameters; total cholesterol (TC), Triglyceride (TG), high density lipoprotein- cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), very low density lipoprotein-cholesterol (VLDL-C) and the atherogenic ratio (LDL-C/HDL-C), in order to register the normal ranges and mean values of these measured parameters in Iraqi healthy racing horses. Results showed that the range and mean values ± standard error of sg were: 33.3 – 6.71 mmol/l and 5.17±0.07 mmol/l, respectively, whereas the TC was 2.07 – 4.22 mmol/l and 3.01±0.05 mmol/l, TG 0.6 – 1.47 mmol/l and 1.06±0.02 mmol/l, HDL-C 0.93 – 2.25 mmol/l and 1.50±0.03 mmol/l, LDL-C 0.10 – 2.12 mmol/l and 0.91±0.04 mmol/l, VLDL-C 0.31 -0.67 mmol/l and 0.55±0.02 mmol/l, respectively and the atherogenic ratio 0.66±0.03. The data present reference values and mean ± SE for sg and lipid profile parameters in healthy racing horses in Baghdad

A mobile-programmable smart mirror for ambient IoT environments

© 2017 IEEE. The purpose of this paper is to present a smart interactive mirror interface. In this paper, we describe the design and development of a futuristic mirror that offers simplified and customisable services to the home environment. On a par with the recent advances in the Internet of Things standards and applications, the mirror is designed to enable residents to control the household smart appliances and access personalised services; ensuring convenience in accessing these services with the slightest possible user intervention. The multipurpose user-friendly functionalities of the proposed mirror interface provide users with the versatility needed for better management and integration of daily tasks. A service oriented approach is adopted in the architecture of the proposed system. It consists mainly of two mobile applications devoted to the customisation of user profiles, which are displayed on the smart mirror interface once successfully paired. Moreover, in the proposed system, emphasis is particularly given to the user profile personalisation, as well as planned system interactivity and adaptability. Hence, the proposed system is set apart from others for its ease of use as well as its provision of various customised information services for user profile generation

6-thioguanine treatment in inflammatory bowel disease: A critical appraisal by a European 6-TG working party

Recently, the suggestion to use 6-thioguanine (6-TG) as an alternative thiopurine in patients with inflammatory bowel disease (IBD) has been discarded due to reports about possible (hepato) toxicity. During meetings arranged in Vienna and Prague in 2004, European experts applying 6-TG further on in IBD patients presented data on safety and efficacy of 6-TG. After thorough evaluation of its risk-benefit ratio, the group consented that 6-TG may still be considered as a rescue drug in stringently defined indications in IBD, albeit restricted to a clinical research setting. As a potential indication for administering 6-TG, we delineated the requirement for maintenance therapy as well as intolerance and/or resistance to aminosalicylates, azathioprine, 6-mercaptopurine, methotrexate and infliximab. Furthermore, indications are preferred in which surgery is thought to be inappropriate. The standard 6-TG dosage should not exceed 25 mg daily. Routine laboratory controls are mandatory in short intervals. Liver biopsies should be performed after 6-12 months, three years and then three-yearly accompanied by gastroduodenoscopy, to monitor for potential hepatotoxicity, including nodular regenerative hyperplasia (NRH) and veno-occlusive disease (VOD). Treatment with 6-TG must be discontinued in case of overt or histologically proven hepatotoxicity. Copyright (c) 2006 S. Karger AG, Basel

Dried blood spot UHPLC-MS/MS analysis of oseltamivir and oseltamivircarboxylate—a validated assay for the clinic

The neuraminidase inhibitor oseltamivir (Tamiflu®) is currently the first-line therapy for patients with influenza virus infection. Common analysis of the prodrug and its active metabolite oseltamivircarboxylate is determined via extraction from plasma. Compared with these assays, dried blood spot (DBS) analysis provides several advantages, including a minimum sample volume required for the measurement of drugs in whole blood. Samples can easily be obtained via a simple, non-invasive finger or heel prick. Mainly, these characteristics make DBS an ideal tool for pediatrics and to measure multiple time points such as those needed in therapeutic drug monitoring or pharmacokinetic studies. Additionally, DBS sample preparation, stability, and storage are usually most convenient. In the present work, we developed and fully validated a DBS assay for the simultaneous determination of oseltamivir and oseltamivircarboxylate concentrations in human whole blood. We demonstrate the simplicity of DBS sample preparation, and a fast, accurate and reproducible analysis using ultra high-performance liquid chromatography coupled to a triple quadrupole mass spectrometer. A thorough validation on the basis of the most recent FDA guidelines for bioanalytical method validation showed that the method is selective, precise, and accurate (≤15% RSD), and sensitive over the relevant clinical range of 5–1,500 ng/mL for oseltamivir and 20–1,500 ng/mL for the oseltamivircarboxylate metabolite. As a proof of concept, oseltamivir and oseltamivircarboxylate levels were determined in DBS obtained from healthy volunteers who received a single oral dose of Tamiflu®

Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication

Rationale: Antipsychotic affinity for the histamine H1 receptor and the muscarinic M3 receptor have been associated with the side effects weight gain, and development of diabetes, respectively. Objectives: We investigated polymorphisms of the histamine H1 (HRH1) and muscarinic acetylcholine receptor M3 (CHRM3) receptor genes for an association with body mass index (BMI) and glycated hemoglobin (HbA1c). Methods: We included 430 Caucasian patients with a non-affective psychotic disorder using antipsychotics for at least 3 months. Primary endpoints of the study were cross-sectionally measured BMI and HbA1c; secondary endpoints were obesity and hyperglycaemia. Two single-nucleotide polymorphisms (SNPs) in the HRH1 gene, rs346074 and rs346070, and one SNP in the CHRM3 gene, rs3738435, were genotyped. Our primary hypothesis in this study was an interaction between genotype on BMI and antipsychotic affinity for the H1 and M3 receptor. Results: A significant association of interaction between haplotype rs346074-rs346070 and BMI (p value 0.025) and obesity (p value 0.005) in patients using high-H1 affinity antipsychotics versus patients using low-H1 affinity antipsychotics was found. There was no association of CHRM3 gene variant rs3738435 with BMI, and we observed no association with HbA1c or hyperglycaemia in any of the variants. Conclusions: This study, for the first time, demonstrates a significant association between HRH1 variants and BMI in patients with a psychotic disorder using antipsychotics. In future, genotyping of HRH1 variants may help predicting weight gain in patients using antipsychotics

A preliminary report on the development of a validated tool for measuring psychosocial outcomes for massive weight loss patients

AIM: To validate the newly developed patient report outcome measure (PROM): the Post Bariatric Outcome Tool (PBOT). The tool is designed and developed for massive weight loss patients seeking body contouring procedures. METHOD: The PBOT was piloted with three cohorts: massive weight loss patients seeking body contouring; massive weight loss patients who have had body contouring; and healthy, non-obese subjects as controls matched for age and gender. Each cohort completed two PROMS at week one, and then for a second time at week three. The PROMS used were the new Post Bariatric Outcome Tool (PBOT) and the Derriford Appearance Scale 24 (DAS24). CONCLUSION: The PBOT was shown to be reliable both in terms of its internal consistency and test-retest reliability. Comparison to the DAS24 demonstrated the PBOT to be valid. However, the cohorts were small and responsiveness was not tested. This needs to be tested in further larger validation studies, ideally, with comparison to functional scales such as the SF-36 or other validated massive weight loss body contouring PROMs; such as the Body Q